CUA - Drug Access Listing

Drug Access Listing

English | français
English
Close Filter
Reset

Use the filters below to narrow down the results.

Content was last updated on: 2024-05-01

Oral agents and Outpatient Injections

New Brunswick

FUNDING:

Take-home cancer drugs are covered by the New Brunswick Drug Plans for eligible beneficiaries. Patients not covered by the New Brunswick Drug Plans may have private insurance coverage.

FORMULARIES:

New Brunswick Drug Plans Formulary: Click Here

Drug
(Brand Name)
Manufacturer		 Indication Strength, Route DIN Provincial Funding Eligibility Criteria References Patient Assistance Programs
Abiraterone (Zytiga) Janssen Inc. Generic mCRPC

250 mg tab | 500 mg tab

Multiple

Special Authorization Criteria

Eligibility:

  • Patients with mCRPC

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression

Clinical Notes:

  • Patients must have a good performance status
  • Treatment should be discontinued upon disease progression or unacceptable toxicity

Claim Notes:

  • Initial approval period: 1 year
  • Renewal approval period: 1 year
  1. NB Drug Plans Formulary [3-22]

​Janssen (Janssen BioAdvance Patient Assistance Program): Access Here   
JAMP (JAMP Care): Access Here 
Sentrex Health Solutions: Access Here 
Pharma-science: Access Here 
Apotex: Access Here 
ApoAssist: Access Here
Abiraterone (Zytiga) Janssen Inc. Generic mCSPC

250 mg tab | 500 mg tab

Multiple

Special Authorization Criteria

Eligibility:

  • Abiraterone in combination with ADT for the treatment of patients with mCSPC
  • No prior ADT or are < 6 months of beginning ADT in the metastatic setting

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression

Clinical Notes:

  • Patients must have a good performance status
  • Treatment should be discontinued upon disease progression or unacceptable toxicity

Claim Notes:

  • Initial approval period: 1 year
  • Renewal approval period: 1 year
  1. NB Drug Plans Formulary [3-22]

​Janssen (Janssen BioAdvance Patient Assistance Program): Access Here   
JAMP (JAMP Care): Access Here 
Sentrex Health Solutions: Access Here 
Pharma-science: Access Here 
Apotex: Access Here 
ApoAssist: Access Here
Alendronate Generic Osteoporosis

10 mg Tab | 70 mg PO

Multiple

Regular benefit
  1. NB Drug Plans Formulary [3-22]

Apotex: Access Here
Apalutamide (Erleada) Janssen Inc. nmCRPC

Tablet, PO, 60mg, 240mg

02478374

Special Authorization Criteria

Eligibility:

  • Apalutamide in combination with ADT for the treatment of patients with nmCRPC who meet all the following criteria:
  • No detectable distant metastases by either CT, MRI or technetium-99m bone scan
  • PSADT ≤ 10 months during continuous ADT (ie, high risk of developing metastases)

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of radiographic disease progression

Clinical Notes:

  • Castration-resistance must be demonstrated during continuous ADT and is defined as a
    ≥ 3 rises in PSA, measured ≥ 1 week apart, with the last PSA > 2 mcg/L
  • Castrate levels of testosterone must be maintained throughout treatment
  • Patients must have a good performance status and no risk factors for seizures
  • Treatment should be discontinued upon radiographic disease progression or unacceptable toxicity

Claim Notes:

  • Requests for apalutamide will not be considered for patients who experience disease progression on enzalutamide or darolutamide
  • Initial approval period: 1 year
  • Renewal approval period: 1 year

**60 mg tablet funded, 240 mg tablet pending provincial funding decision
  1. NB Drug Plans Formulary [3-22]

Janssen BioAdvance Patient Assistance Program: Access Here

 
Apalutamide (Erleada) Janssen Inc. mCSPC

Tablet, PO, 60mg, 240mg

02478374

Special Authorization Criteria

Eligibility:

  • Apalutamide in combination with ADT for the treatment of patients with mCSPC
  • No prior ADT or are < 6 months of beginning ADT in the metastatic setting

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression

Clinical Notes:

  • Patients must have a good performance status and no risk factors for seizures
  • Treatment should be discontinued upon disease progression or unacceptable toxicity

Claim Notes:

  • Requests for apalutamide will not be considered for patients who experience disease progression on enzalutamide
  • Initial approval period: 1 year
  • Renewal approval period: 1 year

**60 mg tablet funded, 240 mg tablet pending provincial funding decision
  1. NB Drug Plans Formulary [3-22]

Janssen BioAdvance Patient Assistance Program: Access Here
Darolutamide (Nubeqa) Bayer nmCRPC

300 mg Tab

02496348

Special Authorization Criteria

Eligibility:

  • In combination with ADT for the treatment of patients with nmCRPC
  • PSADT ≤ 10 months during continuous ADT (ie, high risk of developing metastases)

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of radiographic disease progression

Clinical Notes:

  • Castration-resistance must be demonstrated during continuous ADT and is defined as a
    ≥ 3 rises in PSA, measured ≥ 1 week apart, with the last PSA > 2 mcg/L
  • Castrate levels of testosterone must be maintained throughout treatment
  • Patients must have a good performance status
  • Treatment should be discontinued upon radiographic disease progression or unacceptable toxicity

Claim Notes:

  • Requests for darolutamide will not be considered for patients who experience disease progression on apalutamide or enzalutamide
  • Initial approval period: 1 year
  • Renewal approval period: 1 year
  1. NB Drug Plans Formulary [3-22]

Bayer Patient Support Programs: Access Here
Nubeqa Support Services: Access Here

 
Denosumab (Prolia) Amgen Osteoporosis

60 mg / ml

02343541

Special Authorization Criteria

Eligibility:

  • For the treatment of osteoporosis in patients who meet the following criteria:
  • Have a contraindication to oral bisphosphonates
  • High risk for fracture, or refractory or intolerant to other available osteoporosis therapies

Clinical Notes:

  • Refractory is defined as a fragility fracture or evidence of a decline in bone mineral density below pre-treatment baseline levels, despite adherence for one year to other available osteoporosis therapies
  • High fracture risk is defined as:
  • Moderate 10-year fracture risk (10% to 20%) as defined by the CAROC tool or the FRAX tool with a prior fragility fracture, OR
  • High 10-year fracture risk (≥ 20%) as defined by the CAROC or FRAX tool
  1. NB Drug Plans Formulary [3-22]

ProVital Program: Access Here
Denosumab (Prolia) Amgen mCRPC + Bone mets

120 mg / 1.7 ml vial

02368153

Special Authorization Criteria

Eligibility:

  • For the prevention of skeletal-related events (SREs) in patients with CRPC
  • ≥ 1 documented bone metastases
  • ECOG PS of 0-2*

* patients who are asymptomatic and those who are symptomatic and in bed less than 50% of the time
  1. NB Drug Plans Formulary  [3-22]

The VICTORY Program: Access Here
Enzalutamide (Xtandi) Astellas mCRPC

40 mg Cap

02407329

Special Authorization Criteria

Eligibility:

  • Patients with mCRPC

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression

Clinical Notes:

  • Patients must have a good performance status and no risk factors for seizures
  • Treatment should be discontinued upon disease progression or unacceptable toxicity.

Claim Notes:

  • Requests for enzalutamide will not be considered for patients who experience disease progression on apalutamide or darolutamide
  • Initial approval period: 1 year
  • Renewal approval period: 1 year
  1. NB Drug Plans Formulary [3-22]

Expedite® Patient Assistance Program: Access Here

 
Enzalutamide (Xtandi) Astellas nmCRPC

40 mg Cap

02407329

Special Authorization Criteria

Eligibility:

  • Enzalutamide in combination with ADT for the treatment of patients with nmCRPC
  • PSADT ≤ 10 months during continuous ADT (ie, high risk of developing metastases)

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of radiographic disease progression

Clinical Notes:

  • Castration-resistance must be demonstrated during continuous ADT and is defined as a
    ≥ 3 rises in PSA, measured ≥1 week apart, with the last PSA > 2 mcg/L
  • Castrate levels of testosterone must be maintained throughout treatment
  • Patients must have a good performance status and no risk factors for seizures
  • Treatment should be discontinued upon radiographic disease progression or unacceptable toxicity

Claim Notes:

  • Requests for enzalutamide will not be considered for patients who experience disease progression on apalutamide or darolutamide
  • Initial approval period: 1 year
  • Renewal approval period: 1 year
  1. NB Drug Plans Formulary [3-22]

Expedite® Patient Assistance Program: Access Here
Enzalutamide (Xtandi) Astellas mCSPC

40 mg Cap

02407329

Special Authorization Criteria

Eligibility:

  • Enzalutamide in combination with ADT for the treatment of patients with mCSPC
  • No prior ADT or are < 6 months of beginning ADT in the metastatic setting

Renewal Criteria:

  • Written confirmation that the patient has responded to treatment and there is no evidence of disease progression

Clinical Notes:

  • Patients must have a good performance status and no risk factors for seizures
  • Treatment should be discontinued upon disease progression or unacceptable toxicity

Claim Notes:

  • Requests for enzalutamide will not be considered for patients who experience disease progression on apalutamide
  • Initial approval period: 1 year
  • Renewal approval period: 1 year
  1. NB Drug Plans Formulary [3-22]

Expedite® Patient Assistance Program: Access Here
Niraparib and abiraterone acetate (AKEEGA®) Janssen Inc. nmCRPC

Dual-action tablet, PO/ Comprimé à double action, PO: 100mg niraparib/500mg abiraterone acetate

02538563

Pending provincial funding decision

N/A

Janssen BioAdvance Patient Assistance Program: Access Here
Olaparib (Lynparza) AstraZeneca mCRPC

100 mg tab | 150 mg tab

100mg: 02475200 | 150mg: 02475219

For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who meet all of the following criteria:

  • Deleterious or suspected deleterious germline and/or somatic mutations in the homologous recombination repair (HRR) genes BRCA1, BRCA2 or ATM; and
  • Disease progression on prior treatment with androgen-receptor-axis-targeted (ARAT) therapy.


Renewal Criteria: Written confirmation that the patient has responded to treatment and there is no evidence of disease progression.


Clinical Notes:

  1. Patients must have a good performance status.
  2. Treatment should be discontinued upon disease progression or unacceptable toxicity.


Claim Note: Approval period: 1 year 

NB Drug Plans Formulary

AstraZeneca Patient Support Program: Access Here
AstraZeneca Patient Assistance Program: Access Here